G. Bondar, I. Silacheva, T. Bao, S. Deshmukh, N. Kulkarni, T. Nakade, T. Grogan, D. Elashoff, M. Deng
{"title":"基因组心力衰竭生存预测算法的初步独立验证","authors":"G. Bondar, I. Silacheva, T. Bao, S. Deshmukh, N. Kulkarni, T. Nakade, T. Grogan, D. Elashoff, M. Deng","doi":"10.1080/23808993.2021.1882847","DOIUrl":null,"url":null,"abstract":"ABSTRACT Background Biological determinants of survival in advanced heart failure (AdHF) are linked to systems biological properties of disease severity including age, comorbidities, and frailty. We hypothesize that an algorithm trained to predict the survival in severely ill mechanical circulatory support (MCS) AdHF patients can be independently validated in AdHF-cohorts of varying severity undergoing etiology-specific interventions including heart transplantation (HTx), transcatheter aortic valve replacement (TAVR), and continued guidelines directed medical therapy (GDMT). Research Design & Methods We independently validated our previously published multi-dimensional algorithm, based on 4 clinical parameters and 12 transcriptomic biomarkers, and trained in AdHF patients undergoing MCS-surgery (n = 29), in AdHF patients undergoing TAVR, HTx, MCS, and GDMT-interventions (n = 48). Results In the independent validation cohort, our algorithm demonstrated 71% sensitivity, 90% specificity, 56% positive predictive value, and 95% negative predictive value, allowing for construction of a prototype survival prediction score. While prediction of 1-year survival using clinical parameters alone achieved an AUC = 0.69, addition of 12 differentially expressed genes to the clinical model improved the AUC = 0.90. Conclusions Our initial validation data suggests that the proposed multi-dimensional algorithm is applicable across various AdHF-risk groups and Surgical-Interventional Therapies (S/IT), increasing survival prediction accuracy compared to clinical data alone and warranting further study in larger cohorts.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2021-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1882847","citationCount":"1","resultStr":"{\"title\":\"Initial independent validation of a genomic heart failure survival prediction algorithm\",\"authors\":\"G. Bondar, I. Silacheva, T. Bao, S. Deshmukh, N. Kulkarni, T. Nakade, T. Grogan, D. Elashoff, M. Deng\",\"doi\":\"10.1080/23808993.2021.1882847\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Background Biological determinants of survival in advanced heart failure (AdHF) are linked to systems biological properties of disease severity including age, comorbidities, and frailty. We hypothesize that an algorithm trained to predict the survival in severely ill mechanical circulatory support (MCS) AdHF patients can be independently validated in AdHF-cohorts of varying severity undergoing etiology-specific interventions including heart transplantation (HTx), transcatheter aortic valve replacement (TAVR), and continued guidelines directed medical therapy (GDMT). Research Design & Methods We independently validated our previously published multi-dimensional algorithm, based on 4 clinical parameters and 12 transcriptomic biomarkers, and trained in AdHF patients undergoing MCS-surgery (n = 29), in AdHF patients undergoing TAVR, HTx, MCS, and GDMT-interventions (n = 48). Results In the independent validation cohort, our algorithm demonstrated 71% sensitivity, 90% specificity, 56% positive predictive value, and 95% negative predictive value, allowing for construction of a prototype survival prediction score. While prediction of 1-year survival using clinical parameters alone achieved an AUC = 0.69, addition of 12 differentially expressed genes to the clinical model improved the AUC = 0.90. Conclusions Our initial validation data suggests that the proposed multi-dimensional algorithm is applicable across various AdHF-risk groups and Surgical-Interventional Therapies (S/IT), increasing survival prediction accuracy compared to clinical data alone and warranting further study in larger cohorts.\",\"PeriodicalId\":12124,\"journal\":{\"name\":\"Expert Review of Precision Medicine and Drug Development\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2021-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/23808993.2021.1882847\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Precision Medicine and Drug Development\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23808993.2021.1882847\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2021.1882847","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Initial independent validation of a genomic heart failure survival prediction algorithm
ABSTRACT Background Biological determinants of survival in advanced heart failure (AdHF) are linked to systems biological properties of disease severity including age, comorbidities, and frailty. We hypothesize that an algorithm trained to predict the survival in severely ill mechanical circulatory support (MCS) AdHF patients can be independently validated in AdHF-cohorts of varying severity undergoing etiology-specific interventions including heart transplantation (HTx), transcatheter aortic valve replacement (TAVR), and continued guidelines directed medical therapy (GDMT). Research Design & Methods We independently validated our previously published multi-dimensional algorithm, based on 4 clinical parameters and 12 transcriptomic biomarkers, and trained in AdHF patients undergoing MCS-surgery (n = 29), in AdHF patients undergoing TAVR, HTx, MCS, and GDMT-interventions (n = 48). Results In the independent validation cohort, our algorithm demonstrated 71% sensitivity, 90% specificity, 56% positive predictive value, and 95% negative predictive value, allowing for construction of a prototype survival prediction score. While prediction of 1-year survival using clinical parameters alone achieved an AUC = 0.69, addition of 12 differentially expressed genes to the clinical model improved the AUC = 0.90. Conclusions Our initial validation data suggests that the proposed multi-dimensional algorithm is applicable across various AdHF-risk groups and Surgical-Interventional Therapies (S/IT), increasing survival prediction accuracy compared to clinical data alone and warranting further study in larger cohorts.
期刊介绍:
Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.